Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 13 January, 2020

BioMed X GmbH

BioMed X starts new schizophrenia research program with Boehringer Ingelheim

DGAP-News: BioMed X GmbH / Key word(s): Agreement/Research Update
BioMed X GmbH: BioMed X starts new schizophrenia research program with Boehringer Ingelheim

13.01.2020 / 16:00
The issuer is solely responsible for the content of this announcement.


Press Release

BioMed X starts new schizophrenia research program with Boehringer Ingelheim

Heidelberg, Germany, January 13th, 2020 - BioMed X announced today the start of a new joint research group in collaboration with Boehringer Ingelheim at the BioMed X Innovation Center in Heidelberg. The aim of the new research project is to investigate myelination deficits of the adolescent brain in connection with the development of schizophrenia.

Psychiatric disorders such as schizophrenia emerge as consequence of abnormal brain development and maturation. During adolescence, the brain is reorganized for mature function by processes such as cortical myelination, dendritic arborization, synaptic pruning, and circuit plasticity. Particularly in schizophrenia, there is evidence that genetic, epigenetic and environmental factors negatively affect the balanced functional maturation during adolescence and cumulatively increase the risk for developing symptoms. The new group supported by Boehringer Ingelheim will specifically investigate the myelination deficits, which have been observed in the brains of schizophrenia patients. The innovative approach includes the development of in vitro and in vivo platforms to study oligodendrocyte development and myelination. The goal of the project is to identify novel extrinsic (neuronal) and intrinsic (oligodendrocytic) factors affecting myelination as potential new targets for the prevention of schizophrenia in high-risk individuals.

"We are excited to further extend our collaboration with Boehringer Ingelheim", said Christian Tidona, founder and Managing Director of BioMed X. "This is already our fourth joint research group with Boehringer Ingelheim and our second in the field of psychiatric diseases. The new project will significantly extend our expertise and capabilities in the field of neurosciences."

About BioMed X Innovation Center
The BioMed X Innovation Center is an exciting new collaboration model at the interface between academia and industry. At the center, distinguished early-career scientists recruited from all over the world work jointly on novel pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology and diagnostics. These interdisciplinary project teams conduct outstanding biomedical research in an open-innovation lab facility on the campus of the University of Heidelberg, under the guidance of experienced mentors from academia and industry, while expanding their scientific network and receiving training in entrepreneurship and leadership. Each team is typically sponsored by a corporate pharmaceutical partner of BioMed X. After a fully funded project term, successful projects are internalized into the development pipeline of the respective pharma partner. BioMed X collaborates with pharma companies such as AbbVie, Boehringer Ingelheim, Janssen, Merck and Roche.

Contact:

BioMed X Innovation Center
Dr. Christian Tidona
Managing Director
T: +49 6221 426 1111
E:[email protected]
www.bio.mx



13.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


952319  13.01.2020 

fncls.ssp?fn=show_t_gif&application_id=952319&application_name=news&site_id=financialexpress

a d v e r t i s e m e n t